NEW YORK (GenomeWeb News) – Diagnostic firm Theradiag today announced a partnership with French organizations to develop diagnostic and theranostic tools for rheumatoid arthritis.

The agreement between Theradiag, the French National Center for Scientific Research/The Institute of Molecular Genetics of Montpellier, and the Universities of Montpellier 1 and 2 is focused on identifying microRNA signatures to improve the ability of tests to diagnose RA, to analyze disease activity and severity of the disease, and to predict response to therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.